MiNK Therapeutics, Inc.INKTEarnings & Financial Report
Nasdaq
NextMar 18, 2026
INKT Q3 2025 Key Financial Metrics
Revenue
$55.2K
Gross Profit
N/A
Operating Profit
$-3.2M
Net Profit
$-2.9M
Gross Margin
N/A
Operating Margin
-5772.5%
Net Margin
-5236.0%
YoY Growth
-29.3%
EPS
$-0.65
Financial Flow
MiNK Therapeutics, Inc. Q3 2025 Financial Summary
MiNK Therapeutics, Inc. reported revenue of $55.2K for Q3 2025, with a net profit of $-2.9M (-5236.0% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $55.2K |
|---|---|
| Net Profit | $-2.9M |
| Gross Margin | N/A |
| Operating Margin | -5772.5% |
| Report Period | Q3 2025 |
MiNK Therapeutics, Inc. Annual Revenue by Year
MiNK Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $172.6K).
| Year | Annual Revenue |
|---|---|
| 2024 | $172.6K |
| 2023 | $463.3K |
| 2022 | $253.3K |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $41525 | $16619 | $38360 | $78015 | $39574 | $13517 | $348 | $55151 |
| YoY Growth | -69.2% | -90.1% | -73.8% | -27.3% | -4.7% | -18.7% | -99.1% | -29.3% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $4.6M | $6.9M | $10.3M | $7.4M | $5.7M | $4.3M | $2.5M | $15.0M |
| Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | $-18.1M | $-20.3M | $-16.6M | $-17.6M | $-19.6M | $-21.8M | $-25.2M | $-13.5M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.0M | $-2.5M | $-2.3M | $-3.0M | $-1.7M | $-1.3M | $-1.6M | $-941348 |